Drug Profile
Research programme: antifungals - Essential Therapeutics
Alternative Names: Antifungals research programme - Essential TherapeuticsLatest Information Update: 04 Oct 2004
Price :
$50
*
At a glance
- Originator Essential Therapeutics [CEASED]
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 04 Oct 2004 Essential Therapeutics has closed down
- 04 Oct 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 08 Nov 2001 Microcide Pharmaceuticals has merged with Althexis to form Essential Therapeutics